PEgylated polyester-based nanoncologicals

Current Topics in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1097-1114

  Conte, Claudia ^a   d'Angelo, Ivana ^b   Miro, Agnese ^a   Ungaro, Francesca ^a   Quaglia, Fabiana ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cancer; Chemotherapeutics; Drug targeting; Nanoparticles; Nanotechnology; Polyethylenglycol; Polymers

Indexed keywords

BERBAMINE; BUFALIN; CISPLATIN; CYCLOPAMINE; DOCETAXEL; DOXORUBICIN; DTX PNP; GOSSYPOL; METHOXY POLYETHYLENE GLYCOL; MITOXANTRONE; NANOCARRIER; NANOXEL PM; PACLITAXEL; PEGYLATED POLYESTER NANOCARRIER; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RAPAMYCIN; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; SURVIVIN; TEMOPORFIN; UNCLASSIFIED DRUG; DRUG CARRIER; MACROGOL DERIVATIVE; NANOMATERIAL; POLYESTER;

BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NANOMEDICINE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SOLUBILITY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG DESIGN; HUMAN; SYNTHESIS;

ANIMALS; DRUG CARRIERS; DRUG DESIGN; HUMANS; NANOMEDICINE; NANOSTRUCTURES; POLYESTERS; POLYETHYLENE GLYCOLS;

EID: 84903743564     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140329224243     Document Type: Review

References (169)

1. Iyer, A.K.; Singh, A.; Ganta, S.; Amiji, M.M. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv. Drug Deliv. Rev., 2014, 65, 1784-1802.
2. Heath, J.R.; Davis, M.E. Nanotechnology and cancer. Annu. Rev. Med., 2008, 59, 251-265.
3. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2, 751-760.
4. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
5. Mattheolabakis, G.; Rigas, B.; Constantinides, P.P. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine. (Lond), 2012, 7, 1577-1590.
6. Kamaly, N.; Xiao, Z.; Valencia, P.M.; Radovic-Moreno, A.F.; Farokhzad, O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev., 2012, 41, 2971-3010.
7. Nazir, S.; Hussain, T.; Ayub, A.; Rashid, U.; Macrobert, A.J. Nanomaterials in combating cancer: therapeutic applications and developments. Nanomedicine, 2014, 10, 19-34.
8. d'Angelo I.; Conte, C.; Miro, A.; Quaglia, F.; Ungaro, F. Core-shell nanocarriers for cancer. Part I: biologically-oriented design rules. Exp. Opin. Drug Deliv., 2014, 11, 283-297.
9. Maeda, H.; Nakamura, H.; Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev., 2013, 65, 71-79.
10. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev., 2011, 63, 136-151.
11. Alexis, F.; Pridgen, E.M.; Langer, R.; Farokhzad, O.C. Nanoparticle technologies for cancer therapy. Handb. Exp. Pharmacol., 2010, 55-86.
12. Taurin, S.; Nehoff, H.; Greish, K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J. Control Release, 2012, 164, 265-275.
13. Gref, R.; Domb, A.; Quellec, P.; Blunk, T.; Muller, R.H.; Verbavatz, J.M.; Langer, R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev., 2012, 64, 316-326.
14. Nicolas, J.; Mura, S.; Brambilla, D.; Mackiewicz, N.; Couvreur, P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem. Soc. Rev., 2013, 42, 1147-1235.
15. Duncan, R.; Vicent, M.J. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv. Drug Deliv. Rev., 2013, 65, 60-70.
16. Kirtane, A.; Kalscheuer, S.; Panyam, J. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv. Drug Deliv. Rev., 2013, 65, 1731-1747.
17. Patel, N.R.; Pattni, B.S.; Abouzeid, A.H.; Torchilin, V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv. Drug Deliv. Rev., 2013, 65, 1748-1762.
18. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed Engl., 2010, 49, 6288-6308.
19. Jain, J.; Yenet Ayen, W.; Domb, A.; Kumar, N. Biodegradable Polymers in Clinical Use and Clinical Development, John Wiley & Sons: Hoboken, NJ, USA, 2011.
20. Wei, X.; Gong, C.; Gou, M.; Fu, S.; Guo, Q.; Shi, S.; Luo, F.; Guo, G.; Qiu, L.; Qian, Z. Biodegradable poly(epsilon-caprolactone)-poly(ethylene glycol) copolymers as drug delivery system. Int. J. Pharm., 2009, 381, 1-18.
21. Xiao, R.Z.; Zeng, Z.W.; Zhou, G.L.; Wang, J.J.; Li, F.Z.; Wang, A.M. Recent advances in PEG-PLA block copolymer nanoparticles. Int. J. Nanomedicine., 2010, 5, 1057-1065.
22. Mura, S.; Couvreur, P. Nanotheranostics for personalized medicine. Adv. Drug Deliv. Rev., 2012, 64, 1394-1416.
23. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O.C. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev., 2013.
24. van der Meel, R.; Vehmeijer, L.J.; Kok, R.J.; Storm, G.; van Gaal, E.V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv. Drug Deliv. Rev., 2013, 65, 1284-1298.
25. Sah, H.; Thoma, L.A.; Desu, H.R.; Sah, E.; Wood, G.C. Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int. J. Nanomedicine., 2013, 8, 747-765.
26. Mora-Huertas, C.E.; Fessi, H.; Elaissari, A. Polymer-based nanocapsules for drug delivery. Int. J. Pharm., 2010, 385, 113-142.
27. Couvreur, P.; Barratt, G.; Fattal, E.; Legrand, P.; Vauthier, C. Nanocapsule technology: a review. Crit Rev. Ther. Drug Carrier Syst., 2002, 19, 99-134.
28. Croy, S.R.; Kwon, G.S. Polymeric micelles for drug delivery. Curr. Pharm. Des, 2006, 12, 4669-4684.
29. Attwood, D.; Booth, C.; Yeates, S.G.; Chaibundit, C.; Ricardo, N.M. Block copolymers for drug solubilisation: relative hydrophobicities of polyether and polyester micelle-core-forming blocks. Int. J. Pharm., 2007, 345, 35-41.
30. Torchilin, V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res., 2007, 24, 1-16.
31. Liao, J.; Wang, C.; Wang, Y.; Luo, F.; Qian, Z. Recent advances in formation, properties, and applications of polymersomes. Curr. Pharm. Des, 2012, 18, 3432-3441.
32. Levine, D.H.; Ghoroghchian, P.P.; Freudenberg, J.; Zhang, G.; Therien, M.J.; Greene, M.I.; Hammer, D.A.; Murali, R. Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods, 2008, 46, 25-32.
33. Discher, D.E.; Ahmed, F. Polymersomes. Annu. Rev. Biomed. Eng, 2006, 8, 323-341.
34. Letchford, K.; Burt, H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharm. Biopharm., 2007, 65, 259-269.
35. Lu, Y.; Park, K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm., 2013, 453, 198-214.
36. Discher, D.E.; Ahmed, F. Polymersomes. Annu. Rev. Biomed. Eng, 2006, 8, 323-341.
37. Christian, D.A.; Cai, S.; Bowen, D.M.; Kim, Y.; Pajerowski, J.D.; Discher, D.E. Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur. J. Pharm. Biopharm., 2009, 71, 463-474.
38. Vauthier, C.; Bouchemal, K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res., 2009, 26, 1025-1058.
39. Perez, C.; Sanchez, A.; Putnam, D.; Ting, D.; Langer, R.; Alonso, M.J. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Control Release, 2001, 75, 211-224.
40. Taden, A.; Landfester, K.; Antonietti, M. Crystallization of dyes by directed aggregation of colloidal intermediates: a model case. Langmuir, 2004, 20, 957-961.
41. Ungaro, F.; Conte, C.; Ostacolo, L.; Maglio, G.; Barbieri, A.; Arra, C.; Misso, G.; Abbruzzese, A.; Caraglia, M.; Quaglia, F. Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. Nanomedicine., 2012, 8, 637-646.
42. Conte, C.; Ungaro, F.; Maglio, G.; Tirino, P.; Siracusano, G.; Sciortino, M.T.; Leone, N.; Palma, G.; Barbieri, A.; Arra, C.; Mazzaglia, A.; Quaglia, F. Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn(II)-phthalocyanine inspired by combination therapy for cancer. J. Control Release, 2013, 167, 40-52.
43. Maglio, G.; Nicodemi, F.; Conte, C.; Palumbo, R.; Tirino, P.; Panza, E.; Ianaro, A.; Ungaro, F.; Quaglia, F. Nanocapsules based on linear and Y-shaped 3-miktoarm star-block PEO-PCL copolymers as sustained delivery system for hydrophilic molecules. Biomacromolecules., 2011, 12, 4221-4229.
44. Yang, Z.L.; Li, X.R.; Yang, K.W.; Liu, Y. Amphotericin B-loaded poly(ethylene glycol)-poly(lactide) micelles: preparation, freeze-drying, and in vitro release. J. Biomed. Mater. Res. A, 2008, 85, 539-546.
45. Lemoine, D.; Francois, C.; Kedzierewicz, F.; Preat, V.; Hoffman, M.; Maincent, P. Stability study of nanoparticles of poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials, 1996, 17, 2191-2197.
46. Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev., 2006, 58, 1688-1713.
47. Zambaux, M.F.; Bonneaux, F.; Gref, R.; Dellacherie, E.; Vigneron, C. MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. J. Biomed. Mater. Res., 1999, 44, 109-115.
48. De Jaeghere, F.; Allemann, E.; Leroux, J.C.; Stevels, W.; Feijen, J.; Doelker, E.; Gurny, R. Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: influence on physical stability and in vitro cell uptake. Pharm. Res., 1999, 16, 859-866.
49. Webster, D.M.; Sundaram, P.; Byrne, M.E. Injectable nanomaterials for drug delivery: Carriers, targeting moieties, and therapeutics. Eur. J. Pharm. Biopharm., 2013, 84, 1-20.
50. Chrastina, A.; Massey, K.A.; Schnitzer, J.E. Overcoming in vivo barriers to targeted nanodelivery. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol., 2011, 3, 421-437.
51. Choi, H.S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J.P.; Itty, I.B.; Bawendi, M.G.; Frangioni, J.V. Renal clearance of quantum dots. Nat. Biotechnol., 2007, 25, 1165-1170.
52. Bertrand, N.; Leroux, J.C. The journey of a drug-carrier in the body: An anatomo-physiological perspective. J. Control. Rel., 2012, 161, 152-163.
53. Owens, D.E., III; Peppas, N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm., 2006, 307, 93-102.
54. Gao, H.; He, Q. The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior. Expert. Opin. Drug Deliv., 2014, 11, 409-420.
55. Amoozgar, Z.; Yeo, Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip. Rev Nanomed Nanobiotechnol, 2012, 4, 219-233.
56. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
57. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42, 463-478.
58. Gref, R.; Luck, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Muller, R.H. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces., 2000, 18, 301-313.
59. Laverman, P.; Carstens, M.G.; Boerman, O.C.; Dams, E.T.; Oyen, W.J.; van, R.N.; Corstens, F.H.; Storm, G. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J. Pharmacol. Exp. Ther., 2001, 298, 607-612.
60. Suzuki, T.; Ichihara, M.; Hyodo, K.; Yamamoto, E.; Ishida, T.; Kiwada, H.; Ishihara, H.; Kikuchi, H. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int. J. Pharm., 2012, 436, 636-643.
61. Ishida, T.; Kiwada, H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm., 2008, 354, 56-62.
62. Saadati, R.; Dadashzadeh, S.; Abbasian, Z.; Soleimanjahi, H. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug. Pharm. Res., 2013, 30, 985-995.
63. Ishihara, T.; Takeda, M.; Sakamoto, H.; Kimoto, A.; Kobayashi, C.; Takasaki, N.; Yuki, K.; Tanaka, K.; Takenaga, M.; Igarashi, R.; Maeda, T.; Yamakawa, N.; Okamoto, Y.; Otsuka, M.; Ishida, T.; Kiwada, H.; Mizushima, Y.; Mizushima, T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res., 2009, 26, 2270-2279.
64. Abu Lila, A.S.; Nawata, K.; Shimizu, T.; Ishida, T.; Kiwada, H. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int. J. Pharm., 2013, 456, 235-242.
65. Abu Lila, A.S.; Kiwada, H.; Ishida, T. The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. J. Control Release, 2013, 172, 38-47.
66. Venditto, V.J.; Szoka, F.C., Jr. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev., 2013, 65, 80-88.
67. Florence, A.T. Targeting nanoparticles: the constraints of physical laws and physical barriers. J. Control Release, 2012, 164, 115-124.
68. Ruenraroengsak, P.; Cook, J.M.; Florence, A.T. Nanosystem drug targeting: Facing up to complex realities. J. Control Release, 2010, 141, 265-276.
69. Kyle, A.H.; Huxham, L.A.; Yeoman, D.M.; Minchinton, A.I. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin. Cancer Res., 2007, 13, 2804-2810.
70. Werner, M.E.; Cummings, N.D.; Sethi, M.; Wang, E.C.; Sukumar, R.; Moore, D.T.; Wang, A.Z. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 2013, 86, 463-468.
71. Paclitaxel-loaded polymeric micelle-Clinical trials at NCI. http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=11956317 (Accessed March 7, 2014).
72. Lee, S.W.; Yun, M.H.; Jeong, S.W.; In, C.H.; Kim, J.Y.; Seo, M.H.; Pai, CM.; Kim, S.O. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM using polymer-based delivery system. J. Control Release, 2011, 155, 262-271.
73. Chen, H.; Kim, S.; He, W.; Wang, H.; Low, P.S.; Park, K.; Cheng, J.X. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir, 2008, 24, 5213-5217.
74. Jung, J.; Park, S.J.; Chung, H.K.; Kang, H.W.; Lee, S.W.; Seo, M.H.; Park, H.J.; Song, S.Y.; Jeong, S.Y.; Choi, E.K. Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 2012, 84, e77-e83.
75. A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies. http://clinicaltrials.gov/ct2/show/NCT01103791?term=NCT01103791&rank=1 (Accessed March 7, 2014).
76. Rojnik, M.; Kocbek, P.; Moret, F.; Compagnin, C; Celotti, L.; Bovis, M.J.; Woodhams, J.H.; Macrobert, A.J.; Scheglmann, D.; Helfrich, W.; Verkaik, M.J.; Papini, E.; Reddi, E.; Kos, J. In vitro and in vivo characterization of temoporfin-loaded PEGylated PLGA nanoparticles for use in photodynamic therapy. Nanomedicine. (Lond), 2012, 7, 663-677.
77. Danhier, F.; Lecouturier, N.; Vroman, B.; Jerome, C; Marchand-Brynaert, J.; Feron, O.; Preat, V. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control Release, 2009, 133, 11-17.
78. Tao, W.; Zeng, X.; Liu, T.; Wang, Z.; Xiong, Q.; Ouyang, C; Huang, L.; Mei, L. Docetaxel-loaded nanoparticles based on star-shaped mannitol-core PLGA-TPGS diblock copolymer for breast cancer therapy. Acta Biomater., 2013, 9, 8910-8920.
79. Li, M.; Panagi, Z.; Avgoustakis, K.; Reineke, J. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content. Int. J. Nanomedicine, 2012, 7, 1345-1356.
80. Avgoustakis, K.; Beletsi, A.; Panagi, Z.; Klepetsanis, P.; Livaniou, E.; Evangelatos, G.; Ithakissios, D.S. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGArÇômPEG nanoparticles. Inter. J. Pharm., 2003, 259, 115-127.
81. Liu, Q.; Li, R.; Zhu, Z.; Qian, X.; Guan, W.; Yu, L.; Yang, M.; Jiang, X.; Liu, B. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int. J. Pharm., 2012, 430, 350-358.
82. Miller, T.; Breyer, S.; van, C.G.; Mier, W.; Haberkorn, U.; Geissler, S.; Voss, S.; Weigandt, M.; Goepferich, A. Premature drug release of polymeric micelles and its effects on tumor targeting. Int. J. Pharm., 2013, 445, 117-124.
83. Li, Y.; Qi, X.R.; Maitani, Y.; Nagai, T. PEG-PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations. Nanotechnology, 2009, 20, 055106.
84. Liu, J.; Zeng, F.; Allen, C. In vivo fate of unimers and micelles of a polyethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration. Eur. J. Pharm. Biopharm., 2007, 65, 309-319.
85. Saviç, R.; Azzam, T.; Eisenberg, A.; Maysinger, D. Assessment of the Integrity of Poly(caprolactone)-b-poly(ethylene oxide) Micelles under Biological Conditions TÇë A Fluorogenic-Based Approach. Langmuir, 2006, 22, 3570-3578.
86. Letchford, K.; Burt, H.M. Copolymer micelles and nanospheres with different in vitro stability demonstrate similar paclitaxel pharmacokinetics. Mol. Pharm., 2012, 9, 248-260.
87. Gong, C; Xie, Y.; Wu, Q.; Wang, Y.; Deng, S.; Xiong, D.; Liu, L.; Xiang, M.; Qian, Z.; Wei, Y. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale, 2012, 4, 6004-6017.
88. Dubey, N.; Shukla, J.; Hazari, P.P.; Varshney, R.; Ganeshpurkar, A.; Mishra, A.K.; Trivedi, P.; Bandopadhaya, G.P. Preparation and biological evaluation of paclitaxel loaded biodegradable PCL/PEG nanoparticles for the treatment of human neuroendocrine pancreatic tumor in mice. Hell. J. Nucl. Med., 2012, 15, 9-15.
89. Zhang, L.; He, Y.; Yu, M.; Song, C. Paclitaxel-loaded polymeric nanoparticles based on PCL-PEG-PCL: preparation, in vitro and in vivo evaluation. J. Control Release, 2011, 152 Suppl 1, e114-e116.
90. Gao, X.; Wang, B.; Wei, X.; Rao, W.; Ai, F.; Zhao, F.; Men, K.; Yang, B.; Liu, X.; Huang, M.; Gou, M.; Qian, Z.; Huang, N.; Wei, Y. Preparation, characterization and application of star-shaped PCL/PEG micelles for the delivery of doxorubicin in the treatment of colon cancer. Int. J. Nanomedicine, 2013, 8, 971-982.
91. Zhu, L.; Zhang, B.; Lu, X.; Shu, Y.; Liu, B. Delivery of paclitaxel and berbamine by polymeric carriers to cure gastric cancer. Oncol. Res., 2013, 20, 265-274.
92. Cho, H.; Lai, T.C.; Kwon, G.S. Polyethylene glycol)-block-poly(epsilon-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer. J. Control Release, 2013, 166, 1-9.
93. Wan, C.P.; Letchford, K.; Jackson, J.K.; Burt, H.M. The combined use of paclitaxel-loaded nanoparticles with a low-molecular-weight copolymer inhibitor of P-glycoprotein to overcome drug resistance. Int. J. Nanomedicine., 2013, 8, 379-391.
94. Yang, X.Z.; Dou, S.; Sun, T.M.; Mao, C.Q.; Wang, H.X.; Wang, J. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. J. Control Release, 2011, 156, 203-211.
95. Zhao, Z.X.; Gao, S.Y.; Wang, J.C.; Chen, C.J.; Zhao, E.Y.; Hou, W.J.; Feng, Q.; Gao, L.Y.; Liu, X.Y.; Zhang, L.R.; Zhang, Q. Self-assembly nanomicelles based on cationic mPEG-PLA-b-Polyarginine(R15) triblock copolymer for siRNA delivery. Biomaterials, 2012, 33, 6793-6807.
96. Zeng, S.; Xiong, M.P. Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1). Biomaterials, 2013, 34, 6882-6892.
97. Bae, Y.H. Drug targeting and tumor heterogeneity. J. Control Release, 2009, 133, 2-3.
98. Danhier, F.; Feron, O.; Preat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Rel., 2010, 148, 135-146.
99. Johannessen, T.C.; Wagner, M.; Straume, O.; Bjerkvig, R.; Eikesdal, H.P. Tumor vasculature: the Achilles' heel of cancer? Expert. Opin. Ther. Targets., 2013, 17, 7-20.
100. Sanna, V.; Sechi, M. Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine., 2012, 8 Suppl 1, S31-S36.
101. BIND-014. http://bindtherapeutics.com/pipeline/BIND014.html (Accessed March 7, 2014).
102. Liu, C.W.; Lin, W.J. Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin. Int. J. Nanomedicine, 2012, 7, 4749-4767.
103. Fonge, H.; Huang, H.; Scollard, D.; Reilly, R.M.; Allen, C. Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles. J. Control Release, 2012, 157, 366-374.
104. Liu, P.; Qin, L.; Wang, Q.; Sun, Y.; Zhu, M.; Shen, M.; Duan, Y. cRGD-functionalized mPEG-PLGA-PLL nanoparticles for imaging and therapy of breast cancer. Biomaterials, 2012, 33, 6739-6747.
105. Yin, P.; Wang, Y.; Qiu, Y.; Hou, L.; Liu, X.; Qin, J.; Duan, Y.; Liu, P.; Qiu, M.; Li, Q. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int. J. Nanomedicine, 2012, 7, 3961-3969.
106. Wang, Y.; Liu, P.; Qiu, L.; Sun, Y.; Zhu, M.; Gu, L.; Di, W.; Duan, Y. Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials, 2013, 34, 4068-4077.
107. Guo, J.; Gao, X.; Su, L.; Xia, H.; Gu, G.; Pang, Z.; Jiang, X.; Yao, L.; Chen, J.; Chen, H. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials, 2011, 32, 8010-8020.
108. Gao, H.; Qian, J.; Yang, Z.; Pang, Z.; Xi, Z.; Cao, S.; Wang, Y.; Pan, S.; Zhang, S.; Wang, W.; Jiang, X.; Zhang, Q. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials, 2012, 33, 6264-6272.
109. Hong, G.B.; Zhou, J.X.; Yuan, R.X. Folate-targeted polymeric micelles loaded with ultrasmall superparamagnetic iron oxide: combined small size and high MRI sensitivity. Int. J. Nanomedicine, 2012, 7, 2863-2872.
110. Yoo, H.S.; Park, T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control Release, 2004, 96, 273-283.
111. Yadav, A.K.; Mishra, P.; Jain, S.; Mishra, P.; Mishra, A.K.; Agrawal, G.P. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J. Drug Target, 2008, 16, 464-478.
112. Zeng, X.; Tao, W.; Mei, L.; Huang, L.; Tan, C.; Feng, S.S. Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials, 2013, 34, 6058-6067.
113. Luo, G.; Yu, X.; Jin, C.; Yang, F.; Fu, D.; Long, J.; Xu, J.; Zhan, C.; Lu, W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int. J. Pharm., 2010, 385, 150-156.
114. Chrastina, A.; Massey, K.A.; Schnitzer, J.E. Overcoming in vivo barriers to targeted nanodelivery. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol., 2011, 3, 421-437.
115. Salvati, A.; Pitek, A.S.; Monopoli, M.P.; Prapainop, K.; Bombelli, F.B.; Hristov, D.R.; Kelly, P.M.; Aberg, C.; Mahon, E.; Dawson, K.A. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol., 2013, 8, 137-143.
116. Lee, H.; Fonge, H.; Hoang, B.; Reilly, R.M.; Allen, C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm, 2010, 7, 1195-1208.
117. Valencia, P.M.; Hanewich-Hollatz, M.H.; Gao, W.; Karim, F.; Langer, R.; Karnik, R.; Farokhzad, O.C. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials, 2011, 32, 6226-6233.
118. Preiss, M.R.; Bothun, G.D. Stimuli-responsive liposome-nanoparticle assemblies. Expert. Opin. Drug Deliv., 2011, 8, 1025-1040.
119. Gao, W.; Chan, J.M.; Farokhzad, O.C. pH-Responsive nanoparticles for drug delivery. Mol. Pharm., 2010, 7, 1913-1920.
120. Zhu, L.; Torchilin, V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr. Biol. (Camb.), 2013, 5, 96-107.
121. Romberg, B.; Hennink, W.E.; Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm Res., 2008, 25, 55-71.
122. Yin, H.; Lee, E.S.; Kim, D.; Lee, K.H.; Oh, K.T.; Bae, Y.H. Physicochemical characteristics of pH-sensitive poly(L-histidine)-b-poly(ethylene glycol)/poly(L-lactide)-b-poly(ethylene glycol) mixed micelles. J. Control Release, 2008, 126, 130-138.
123. Lee, E.S.; Gao, Z.; Kim, D.; Park, K.; Kwon, I.C.; Bae, Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J. Control Release., 2008, 129, 228-236.
124. Chen, C.Y.; Kim, T.H.; Wu, W.C.; Huang, C.M.; Wei, H.; Mount, C.W.; Tian, Y.; Jang, S.H.; Pun, S.H.; Jen, A.K. pH-dependent, thermosensitive polymeric nanocarriers for drug delivery to solid tumors. Biomaterials, 2013, 34, 4501-4509.
125. Zhao, B.X.; Zhao, Y.; Huang, Y.; Luo, L.M.; Song, P.; Wang, X.; Chen, S.; Yu, K.F.; Zhang, X.; Zhang, Q. The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel. Biomaterials, 2012, 33, 2508-2520.
126. Chen, Y.C.; Lo, C.L.; Lin, Y.F.; Hsiue, G.H. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials, 2013, 34, 1115-1127.
127. Gu, G.; Xia, H.; Hu, Q.; Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Tu, Y.; Pang, Z.; Song, Q.; Yao, L.; Chen, H.; Gao, X.; Chen, J. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials, 2013, 34, 196-208.
128. Liu, Q.; Li, R.T.; Qian, H.Q.; Yang, M.; Zhu, Z.S.; Wu, W.; Qian, X.P.; Yu, L.X.; Jiang, X.Q.; Liu, B.R. Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(varepsilon-caprolactone) nano-particles. Int. J. Nanomedicine., 2012, 7, 281-295.
129. Prabhu, P.; Patravale, V. The upcoming field of theranostic nanomedicine: an overview. J. Biomed. Nanotechnol., 2012, 8, 859-882.
130. Ahmed, N.; Fessi, H.; Elaissari, A. Theranostic applications of nanoparticles in cancer. Drug Discov. Today, 2012, 17, 928-934.
131. Svenson, S. Theranostics: are we there yet? Mol. Pharm., 2013, 10, 848-856.
132. Xie, J.; Lee, S.; Chen, X. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev., 2010, 62, 1064-1079.
133. Choi, K.Y.; Liu, G.; Lee, S.; Chen, X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale., 2012, 4, 330-342.
134. Wang, C.; Ravi, S.; Martinez, G.V.; Chinnasamy, V.; Raulji, P.; Howell, M.; Davis, Y.; Mallela, J.; Seehra, M.S.; Mohapatra, S. Dual-purpose magnetic micelles for MRI and gene delivery. J. Control Release, 2012, 163, 82-92.
135. Wang, H.; Wu, Y.; Zhao, R.; Nie, G. Engineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy. Adv. Mater., 2013, 25, 1616-1622.
136. Wagh, A.; Jyoti, F.; Mallik, S.; Qian, S.; Leclerc, E.; Law, B. Polymeric nanoparticles with sequential and multiple FRET cascade mechanisms for multicolor and multiplexed imaging. Small, 2013, 9, 2129-2139.
137. Cai, Z.; Wang, Y.; Zhu, L.J.; Liu, Z.Q. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr. Drug Metab, 2010, 11, 197-207.
138. Mei, L.; Zhang, Z.; Zhao, L.; Huang, L.; Yang, X.L.; Tang, J.; Feng, S.S. Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv. Drug Deliv. Rev., 2013, 65, 880-890.
139. Bebawy, M.; Sze, D.M. Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics. Curr. Cancer Drug Targets., 2008, 8, 47-52.
140. Malingre, M.M.; Beijnen, J.H.; Schellens, J.H. Oral delivery of taxanes. Invest New Drugs, 2001, 19, 155-162.
141. Zabaleta, V.; Ponchel, G.; Salman, H.; Agueros, M.; Vauthier, C.; Irache, J.M. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur. J. Pharm. Biopharm., 2012, 81, 514-523.
142. Feng, S.S.; Mei, L.; Anitha, P.; Gan, C.W.; Zhou, W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials, 2009, 30, 3297-3306.
143. Zhao, L.; Feng, S.S. Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J. Pharm. Sci., 2010, 99, 3552-3560.
144. Iqbal, J.; Hombach, J.; Matuszczak, B.; Bernkop-Schnurch, A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J. Control Release, 2010, 147, 62-69.
145. Shieh, M.J.; Hsu, C.Y.; Huang, L.Y.; Chen, H.Y.; Huang, F.H.; Lai, P.S. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J. Control Release, 2011, 152, 418-425.
146. Kruijtzer, C.M.; Beijnen, J.H.; Schellens, J.H. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist, 2002, 7, 516-530.
147. Collnot, E.M.; Baldes, C.; Wempe, M.F.; Hyatt, J.; Navarro, L.; Edgar, K.J.; Schaefer, U.F.; Lehr, C.M. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J. Control Release, 2006, 111, 35-40.
148. Tobio, M.; Sanchez, A.; Vila, A.; Soriano, I., I; Evora, C.; Vila-Jato, J.L.; Alonso, M.J. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B Biointerfaces., 2000, 18, 315-323.
149. Khalil, N.M.; do Nascimento, T.C.; Casa, D.M.; Dalmolin, L.F.; de Mattos, A.C.; Hoss, I.; Romano, M.A.; Mainardes, R.M. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B Biointerfaces, 2013, 101, 353-360.
150. Ensign, L.M.; Cone, R.; Hanes, J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev., 2012, 64, 557-570.
151. Tang, B.C.; Dawson, M.; Lai, S.K.; Wang, Y.Y.; Suk, J.S.; Yang, M.; Zeitlin, P.; Boyle, M.P.; Fu, J.; Hanes, J. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc. Natl. Acad. Sci. U. S. A, 2009, 106, 19268-19273.
152. Patton, J.S.; Brain, J.D.; Davies, L.A.; Fiegel, J.; Gumbleton, M.; Kim, K.J.; Sakagami, M.; Vanbever, R.; Ehrhardt, C. The particle has landed--characterizing the fate of inhaled pharmaceuticals. J. Aerosol Med. Pulm. Drug Deliv., 2010, 23 Suppl 2, S71-S87.
153. Sung, J.C.; Pulliam, B.L.; Edwards, D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol., 2007, 25, 563-570.
154. Azarmi, S.; Roa, W.H.; Lobenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev., 2008, 60, 863-875.
155. Al-Hallak, M.H.; Sarfraz, M.K.; Azarmi, S.; Roa, W.H.; Finlay, W.H.; Lobenberg, R. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther. Deliv., 2011, 2, 1313-1324.
156. Patel, B.; Gupta, V.; Ahsan, F. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. J. Control Release, 2012, 162, 310-320.
157. Karra, N.; Nassar, T.; Laenger, F.; Benita, S.; Borlak, J. Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model. Curr. Cancer Drug Targets, 2013, 13, 11-29.
158. Rogueda, P.G.; Traini, D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert. Opin. Drug Deliv., 2007, 4, 607-620.
159. Zarogoulidis, P.; Chatzaki, E.; Porpodis, K.; Domvri, K.; Hohenforst-Schmidt, W.; Goldberg, E.P.; Karamanos, N.; Zarogoulidis, K. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int. J. Nanomedicine., 2012, 7:1551-1572. doi: 10.2147/IJN.S29997. Epub;%2012 Mar 22., 1551-1572.
160. Sung, J.C.; Pulliam, B.L.; Edwards, D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol., 2007, 25, 563-570.
161. Pulliam, B.; Sung, J.C.; Edwards, D.A. Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin. Drug Deliv., 2007, 4, 651-663.
162. Tsapis, N.; Bennett, D.; Jackson, B.; Weitz, D.A.; Edwards, D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U. S. A, 2002, 99, 12001-12005.
163. Tomoda, K.; Ohkoshi, T.; Hirota, K.; Sonavane, G.S.; Nakajima, T.; Terada, H.; Komuro, M.; Kitazato, K.; Makino, K. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf. B Biointerfaces., 2009, 71, 177-182.
164. Ungaro, F.; d'Angelo, I.; Coletta, C.; d'Emmanuele, V.; Sorrentino, R.; Perfetto, B.; Tufano, M.A.; Miro, A.; La Rotonda, M.I.; Quaglia, F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control Release, 2012, 157, 149-159.
165. Dash, T.K.; Konkimalla, V.B. Poly-small je, Ukrainian-caprolactone based formulations for drug delivery and tissue engineering: A review. J. Control Release, 2012, 158, 15-33.
166. Park, T.G. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. Biomaterials, 1995, 16, 1123-1130.
167. Woo, H.N.; Chung, H.K.; Ju, E.J.; Jung, J.; Kang, H.W.; Lee, S.W.; Seo, M.H.; Lee, J.S.; Lee, J.S.; Park, H.J.; Song, S.Y.; Jeong, S.Y.; Choi, E.K. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int. J. Nanomedicine, 2012, 7, 2197-2208.
168. Zhao, T.; Chen, H.; Dong, Y.; Zhang, J.; Huang, H.; Zhu, J.; Zhang, W. Paclitaxel-loaded poly(glycolide-co-epsilon-capro-lactone)-b-D-alpha-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy. Int. J. Nanomedicine, 2013, 8, 1947-1957.
169. Schleich, N.; Sibret, P.; Danhier, P.; Ucakar, B.; Laurent, S.; Muller, R.N.; Jerome, C.; Gallez, B.; Preat, V.; Danhier, F. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int. J. Pharm., 2013, 447, 94-101.